On May 21, 2026 Pliant Therapeutics, Inc. (Nasdaq: PLRX) reported a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation
Title: Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune Checkpoint Inhibitors
Presenter: Timothy A. Yap, MBBS, Ph.D., University of Texas, M.D. Anderson Cancer Center
Session: Developmental Therapeutics – Immunotherapy
Date: Saturday, May 30, 2026, 1:30 – 4:30 p.m. Central Time
Location: Hall A, Poster 467b
FORTIFY – PLN-101095 Phase 1b Indication Expansion Trial
PLN-101095 is currently being evaluated in Phase 1a/1b open-label, dose-escalation and indication expansion trial (NCT06270706) to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095 when administered orally in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. Pliant is currently enrolling patients in FORTIFY, a Phase 1b open-label, indication expansion trial enrolling three cohorts of patients with non-small cell lung cancer (NSCLC), tumors with high tumor mutational burden or clear cell renal cell carcinoma. Patients will be treated for 14 days with PLN-101095 dosed at 1,000 mg twice daily as monotherapy, after which pembrolizumab will be added as combination therapy.
(Press release, Pliant Therapeutics, MAY 21, 2026, View Source [SID1234665981])